[go: up one dir, main page]

UY30572A1 - N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 - Google Patents

N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2

Info

Publication number
UY30572A1
UY30572A1 UY30572A UY30572A UY30572A1 UY 30572 A1 UY30572 A1 UY 30572A1 UY 30572 A UY30572 A UY 30572A UY 30572 A UY30572 A UY 30572A UY 30572 A1 UY30572 A1 UY 30572A1
Authority
UY
Uruguay
Prior art keywords
piperidin
ftalazin
amidas
modulators
receiver
Prior art date
Application number
UY30572A
Other languages
English (en)
Inventor
Antonius Ter Laak
Tim Wintermantel
Olaf Peters
Bernhard Lindenthal
Gernot Langer
Marcus Koppitz
Bernd Buchmann
Nico Braeuer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY30572A1 publication Critical patent/UY30572A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a ftalazin-1-il-piperidin-4-il-amidas de la formula general I, a procedimientos para su preparacion, así como a su uso para la preparacion de agentes farmacéuticos para el tratamiento de enfermedades e indicaciones que están relacionadas con el receptor EP2.
UY30572A 2006-09-07 2007-09-05 N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 UY30572A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06090159A EP1900731A1 (de) 2006-09-07 2006-09-07 N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren

Publications (1)

Publication Number Publication Date
UY30572A1 true UY30572A1 (es) 2008-05-02

Family

ID=37649444

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30572A UY30572A1 (es) 2006-09-07 2007-09-05 N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2

Country Status (7)

Country Link
US (1) US20080146576A1 (es)
EP (1) EP1900731A1 (es)
AR (1) AR062695A1 (es)
CL (1) CL2007002578A1 (es)
TW (1) TW200817356A (es)
UY (1) UY30572A1 (es)
WO (1) WO2008028689A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
CN102202737B (zh) 2008-11-03 2014-03-26 伊莱利利公司 二取代的2,3-二氮杂萘hedgehog通路拮抗剂
KR101335770B1 (ko) 2008-11-17 2013-12-12 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
EP2358698B1 (en) 2008-11-17 2012-09-05 Eli Lilly and Company Tetrasubstituted pyridazine as hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
HUE034347T2 (en) 2010-09-29 2018-02-28 Intervet Int Bv N-heteroaryl compounds with a cyclic bridge unit for the treatment of parasitic diseases
BR112013006030B1 (pt) 2010-09-29 2020-03-17 Intervet International B.V. Composto e sais ou n-óxidos farmaceuticamente aceitáveis, e, uso do composto
WO2012046132A1 (en) 2010-10-05 2012-04-12 Purdue Pharma L.P. Quinazoline compounds as sodium channel blockers
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
AU2013241854B2 (en) 2012-03-28 2017-11-02 Intervet International B.V. Heteroaryl compounds with cyclic bridging unit for use in the treatment helminth infection
ES2744597T3 (es) 2012-03-28 2020-02-25 Intervet Int Bv Compuestos de heteroarilo con una unidad acíclica como puente
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
RS59911B1 (sr) 2013-10-14 2020-03-31 Eisai R&D Man Co Ltd Selektivno supstituisana jedinjenja hinolina
CA2920791C (en) 2013-10-14 2021-11-16 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
CN116349204A (zh) 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (es) * 1977-06-03 1981-03-07 Pfizer
US4370328A (en) * 1977-11-03 1983-01-25 Pfizer Inc. Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
EP1467738A1 (en) * 2001-10-08 2004-10-20 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus

Also Published As

Publication number Publication date
EP1900731A1 (de) 2008-03-19
WO2008028689A1 (en) 2008-03-13
TW200817356A (en) 2008-04-16
AR062695A1 (es) 2008-11-26
CL2007002578A1 (es) 2008-07-04
US20080146576A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
PE20151065A1 (es) Novedosos derivados de bencimidazol como antagonistas de ep4
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
CR20110509A (es) Composicion farmaceutica
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
MX388468B (es) Compuestos multicíclicos y métodos de uso de los mismos.
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
BRPI0820668A2 (pt) Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
BRPI1013259B8 (pt) moduladores lxr
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
ECSP13012600A (es) CO-cristales y Sales de Inhibidores de CCR3
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
CO6341625A2 (es) Derivados de indol como agentes anticáncer
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170726